Concerning ibogaine-assisted therapy.

SB 5204 requires the University of Washington to conduct a three-year study comparing ibogaine-assisted therapy (administered via licensed clinics in Mexico) to standard opioid use disorder treatments. The study will measure outcomes like reduced opioid use, mortality, cravings, and treatment engagement among adults with opioid use disorder. It directly affects the University of Washington, which must design and execute this research, and future patients if the therapy proves effective. The bill does not authorize ibogaine use but aims to evaluate its potential as an alternative to current treatments like methadone or buprenorphine.